Harmless virus may hold key to safer kidney transplants

NCT ID NCT06829719

Recruiting now Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether monitoring levels of a harmless virus called TTV can help doctors personalize immune-suppressing drugs for kidney transplant patients. The goal is to prevent long-term complications like infections, cancer, and organ rejection. About 600 adults who received a kidney transplant 1-4 years ago will take part. Their treatment will be adjusted based on TTV levels, aiming to find the right balance between preventing rejection and avoiding side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections neoplasm Rejection, Psychology transplant rejection cancer prevention target infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER INFECTION KIDNEY TRANSPLANTATION REJECTION

Contacts and locations

Locations

Département de Néphrologie et Transplantation d'Organes Hôpital Rangueil - CHU de Toulouse
RECRUITING

Toulouse (France), 31059, France
Service de Néphrologie, Dialyse et Transplantation Rénale Nouvel Hôpital Civil
NOT_YET_RECRUITING

Strasbourg (france), 67091, France
Service de Néphrologie-Transplantation-Dialyse I Hôpital Pellegrin I - CHU Bordeaux
NOT_YET_RECRUITING

Bordeaux (France), 33000, France
Service de transplantation, néphrologie et immunologie clinique Hospices Civils de Lyon, Hôpital Edouard Herriot
RECRUITING

Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.